Eleanor Malone
Editor in Chief, Commercial Insights at Generics Bulletin
Editor in Chief, Commercial Insights at In Vivo
Editor in Chief, Commercial Insights at Scrip
Editor in Chief, Commercial Insights, Citeline - Scrip, In Vivo, Generics Bulletin - covering biopharma news and analysis. All views are my own.
Articles
-
1 month ago |
insights.citeline.com | Eleanor Malone
20 Voices: What Does 2025 Hold For Biopharma? Dealmaking, Innovation And Therapeutic BreakthroughsTwenty executives in the biopharma industry outline their expectations for key trends and developments this year. A selection of commentary from a broad industry survey by Scrip. Biopharma leaders consider key emerging trends (jittawit21/Shutterstock)
-
1 month ago |
clinicalleader.com | Eleanor Malone
By Eleanor Malone As the biopharmaceutical industry approaches 2025, clinical trials are set to undergo transformative changes, emphasizing patient-centricity and inclusivity. Here we explore emerging trends that leverage technological advancements, including artificial intelligence (AI) and data analytics, to enhance trial efficiency and accuracy.
-
2 months ago |
insights.citeline.com | Eleanor Malone
Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area AdvancesOncology, Immunology, Cardiometabolism, Neurology DominateOver 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.
-
2 months ago |
insights.citeline.com | Eleanor Malone
Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials TrendsData Science Transforms Data GatheringA revolution is underway. Technology offers the possibility to transform multiple aspects of the traditional gold standard of drug development: the randomized controlled trial. Sharing their insights with Scrip, 30 thought leaders consider how the clinical trial landscape will evolve in 2025.
-
Jan 24, 2025 |
insights.citeline.com | Eleanor Malone
Scrip Asks... What Does 2025 Hold For Biopharma? Part 4: Artificial Intelligence and Data ScienceFrom Sci-Fi To Table Stakes More than 50 executives across industry share their expectations for the impact of AI on the biopharma industry over the coming year. While target identification and drug discovery featured highly, the opportunities to engage with patients and healthcare providers more effectively and the need for suitable regulatory frameworks were also flagged up.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 2K
- Tweets
- 3K
- DMs Open
- No
RT @SarahKarlin: heading to the Senate this afternoon for the Bernie-Insulin makers-PBM showdown.
A group of us @citeline and @norstella are taking part in #RaceforLife in memory of our colleague Maureen Kenny - @scripregmaureen - and we would love to raise as much as possible for cancer research... https://t.co/RoQujzw6VJ
My brilliant, funny, lovely dad.
Andrew Malone obituary https://t.co/rQ1H2YtE5H